Media Center
A multimedia mosaic of moments at GIST
GIST Excellence
[Press Release] AnyGen Co., Ltd., is the first GIST Company to be listed on KOSDAQ
- 엘리스 리
- REG_DATE : 2016.12.21
- HIT : 1037
AnyGen Co., Ltd., is the first GIST Company to be listed on KOSDAQ
□ AnyGen Co., Ltd., was the first company from the Gwangju Institute of Science and Technology (GIST) to be listed on KOSDAQ on December 7, 2016, and a commemorative ceremony was held on December 20, 2017, with more than 150 people in attendance, including GIST President Seung Hyeon Moon.
∘ The ceremony was attended by more than 150 people, including GIST President Seung Hyeon Moon, Gwangju Techno Park President Jeong-chan Bae, affiliated companies, and employees of AnyGen Co., Ltd.
□ AnyGen Co., Ltd., which is a start-up company established in 2000 by Professor Jae Il. Kim of the GIST School of Life Sciences, is the first bio-venture company in Gwangju and Jeonnam province, specializing in the development of peptide biomaterials through continuous research and development over the past 16 years. It was listed on the KOSDAQ market on July 7, 2016.
∘ AnyGen has developed key core technologies (selective folding technology, peptide combination technology, peptide synthesis technology using AG-Tag) for the production of peptide biopharmaceutical materials. By applying this technology, four types of peptide drug materials with high marketability is in the process of development and commercialization. In addition, the company is also commercializing five other products.
∘ AnyGen is currently developing clinical peptides for new drug development for Japanese pharmaceutical companies (Wakamori, Tella, Scrum, NEC, etc.) and drug companies and bio-venture companies, which are currently developing global peptide drugs.
∘ In addition, the recent international standardization of product quality for overseas export of the domestic pharmaceutical industry has been achieved through the addition of PIC/S to the Korea Pharmaceutical Manufacturers" Association (KICP), which has secured global competitiveness in the supply of pharmaceutical peptide materials. In addition, the company focuses on the development of amino acid and peptide drugs for diseases with high market value and unmet medical needs.
∘ Research and development of several pipelines, including AGM-212, a type 2 diabetes treatment agent, and AGM-215, a neuropathic pain treatment, which are currently undergoing preclinical testing.
□ GIST Professor Jae Il. Kim said, "With the listing of the KOSDAQ market, we plan to steadily increase investment in cGMP production and peptide drug R & D through the construction of a second GMP plant. We will do our best to be the best model of a Korean bio-venture company."